Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561078 · ClinicalTrials.gov registry record · Phase 3
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
NCT02561078 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 420 participants.
The verdict
NCT02561078, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in participants with type 2 diabetes mellitus.
Interventions
- DRUG Human regular U-500 insulin (CSII)
- DRUG Human regular U-500 insulin (MDI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2015-10-20 |
| Est. Completion | 2017-05-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02561078
The ClinicalTrials.gov registry entry for NCT02561078 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Human regular U-500 insulin (CSII) is the first listed.
NCT02561078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02561078 about?
NCT02561078 is a clinical study titled "An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus". The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) in participants with type 2 diabetes mellitus.
What is the current status of trial NCT02561078?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2015-10-20. Estimated completion is 2017-05-09.
What interventions are being tested in trial NCT02561078?
The interventions under investigation include: Human regular U-500 insulin (CSII) (DRUG), Human regular U-500 insulin (MDI) (DRUG).
Who is sponsoring clinical trial NCT02561078?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.